We are about to be plunged into a period of dramatic, almost unimaginable change… and the evidence is beginning to show up in the labor market.
Last year was the worst year for corporate layoffs since 2009 – the height of the financial crisis. More than 1.2 million jobs were cut. But one event made it clear that this trend is about to accelerate:
Twitter founder Jack Dorsey laid off 4,000 workers at his company, Block. 40% of his entire company, gone overnight:
“We’re already seeing that the intelligence tools we’re creating are enabling a new way of working which fundamentally changes what it means to build and run a company. And that's accelerating rapidly.”
“I had two options: cut gradually over months or years as this shift plays out, or be honest about where we are and act on it now.I chose the latter.”
Mark my words, more companies will follow this example in the coming months. Layoffs will soar, and millions of workers may be at risk.
The media will blame AI, but as I show in my investigation, this story is much larger, and runs much deeper than just AI technology.
I – and many of the world’s leading experts – believe this could beThe Final Displacement.
An event that will see politicians, companies, and economies rise and fall, the most sacred of our social contracts being rewritten, and our ways of life that’ve stood for generations being swept away in the blink of an eye.
And as you’ll see, history shows us that although these societal shifts always lead to catastrophic losses for those who fail to prepare…
… they also unleash unprecedented wealth building potential for those who understand, and harness, the forces at work.
And whether you ascend to an entirely new level of prosperity and freedom… or are left behind with your standards of living collapsing… that could depend on what you do today.
Because this wealth will only flow toward a select group of individuals… to those who understand the re-alignment we’re in and take the necessary steps to grasp it.
It’s already happening, with Goldman Sachs reporting an average of 1,600 new millionaires being created daily.
While at the same time, tens of millions of ordinary Americans are falling further and further behind…
Not because they’re lazy, reckless, or unwilling to work hard, but simply because they’re the unwitting victims of this Final Displacement.
Today, I’m sharing everything my investigation uncovered.
Along with the steps I’m taking to protect myself, my loved ones, and my financial future… the steps that I’m certain will propel my wealth to an entirely new level.
And that I believe could do the same for your wealth.
Everything is detailed here for you in my documentary.
Good investing,
Porter Stansberry
5 Oversold Large-Cap Stocks That May Be Worth Buying Soon
Author: Ryan Hasson. Date Posted: 3/16/2026.
Key Points
- With a broad market selloff pushing many large-cap stocks into value territory, five stocks in particular are worth watching for potential opportunities.
- Delta Air Lines, JPMorgan Chase, and Bank of America have all fallen sharply this month, pushing their valuations into deep value territory while analysts remain overwhelmingly bullish on each.
- Toyota and Unilever round out the list, with both stocks flashing oversold RSI readings and sitting on key technical support levels despite solid underlying fundamentals.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
A sea of red has swept the market in recent weeks. Inflationary worries are rising, the odds of a Fed rate cut are diminishing, and oil prices are climbing as tensions in the Middle East intensify. What began the year as selling pressure concentrated in mega-cap technology and software stocks—driven by concerns about AI capital spending and competitive moats—has broadened into a market-wide selloff. The layers of fear and uncertainty have taken their toll: the S&P 500 ETF (NYSEARCA: SPY) closed last week down 1.5% and is now more than 3% lower for the year.
Still, when fear pushes fundamentally sound stocks into oversold or deep-value territory, it can create compelling buying opportunities for patient investors. One way to spot those opportunities is the Relative Strength Index (RSI), which flags when a stock may be technically oversold. Another is to compare forward P/E ratios with sector peers to see if a stock has been punished beyond what its earnings outlook supports. With that framework in mind, here are five large-cap stocks worth watching as the selloff deepens.
Delta Air Lines: A Value Signal Hiding Inside a Steep Pullback
Ground-zero (Ad)
San Francisco is the strangest city in America right now—you can hop into a self-driving car and be chauffeured by a robot, but out the window you see addicts slumped in doorways, open-air drug markets, the mentally ill screaming at the sky, and entire city blocks consumed by homeless encampments. It's ground-zero for the most disruptive technological forces of our age, and Erez lives in the Bay Area plugged into the capital, the connections, and the companies reshaping the world—the advancements in AI, blockchain, computing, and biosciences are unlike anything the world has seen before, and a tsunami of disruption is coming for everything all at once. During our most recent broadcast, we exposed what we're calling the most asymmetric opportunity of our careers: an overlooked financial company hiding a multi-billion-dollar blockchain asset Wall Street hasn't priced in—it's one of those rare situations Warren Buffett would describe as raining gold when all you have to do is step outside if you want to get rich.
Watch the broadcast before the window closes nowDelta Air Lines (NYSE: DAL) has been one of the hardest-hit names recently, falling almost 18% this month and more than 15% year to date (YTD). Its RSI has dropped to 34, nearing oversold territory, but the valuation metrics are what stand out: DAL trades at a trailing P/E of 7.7 and a forward P/E approaching 7—levels that historically signal a potential value opportunity.
The key question is whether this is a genuine value opportunity or a value trap. Looking at the fundamentals, the opportunity case appears stronger.
Delta posted record full-year 2025 revenue of $58.3 billion, delivered a 10% operating margin, and generated $4.6 billion in free cash flow—a company record that materially reduced leverage and produced a 12% return on invested capital.
Management is guiding 2026 EPS of $6.50 to $7.50, implying roughly 20% year-over-year growth, alongside free cash flow of $3–$4 billion and a target leverage ratio of about 2x by year-end.
Wall Street is mostly bullish, with a consensus Moderate Buy rating and a price target implying nearly 35% upside from current levels. Institutional activity also favors the stock, with $6.4 billion in inflows over the prior 12 months versus $4 billion in outflows. Technically, DAL is attempting to find support near its 50-day simple moving average (SMA). If it can build a base around the $60 level and confirm a higher low, that could signal stabilization and a potential entry point for longer-term investors.
JPMorgan Chase: Sector Pressure Creates a Window
JPMorgan Chase (NYSE: JPM) has been dragged down with the broader financial sector—the sector ETF is down nearly 11% YTD and more than 7% this month. Concerns about private credit exposure have spread from alternative asset managers to major banks, and JPM has felt the brunt, sliding roughly 9% this month and trading nearly 16% off its 52-week high.
Its RSI has dipped toward 32, approaching short-term oversold territory, while the forward P/E has fallen to about 12—a clear value signal for one of the world's most profitable financial institutions.
That said, technical caution is warranted: the stock is trading below key moving averages and the financial sector remains in a downtrend, so timing an entry matters.
Fundamentally, JPM's performance remains solid. In Q4 2025, the bank reported EPS of $5.23, beating the consensus of $4.93, with quarterly revenue up 7.1% year-over-year to $45.8 billion.
Analysts maintain a Moderate Buy consensus rating and a price target implying nearly 20% upside, making JPM worth watching for signs of sector stabilization.
Bank of America: Deep Value With an Income Kicker
Bank of America (NYSE: BAC) has seen intense selling as well, down about 13% this month and just over 15% YTD for similar reasons as JPMorgan.
The pullback has pushed BAC's valuation into attractive territory: its forward P/E is around 9.4, and the stock yields about 2.5%, offering income to investors willing to be patient.
Technically, BAC is trading below key moving averages and the financial sector has yet to find firm footing, so many investors may prefer to wait for the stock and sector to form a base before adding to positions.
Analysts are constructive overall, with a Moderate Buy consensus rating and a price target near $60.30, implying close to 30% upside from current levels—one of the more attractive risk-reward setups on this list if the sector turns.
Toyota Motor Corporation: An Earnings Beat Washed Out by Market Fear
Toyota Motor Corporation (NYSE: TM) has fallen more than 15% from its February highs and is down about 13% this month, despite delivering a strong earnings beat just weeks ago.
The automaker reported Q3 fiscal 2026 EPS of $6.26 on Feb. 6, beating the consensus estimate of $4.35 by $1.91. The stock initially rallied, but has since been swept lower by the broader market decline.
That disconnect between business performance and share price is precisely what makes Toyota worth watching. The stock now carries an oversold RSI and a forward P/E of about 9.78—attractive for a company of Toyota's scale and global reach.
Importantly, Toyota remains above its 200-day SMA, suggesting the longer-term uptrend is still intact despite near-term turbulence. Net institutional inflows over the past 12 months and an analyst consensus Moderate Buy rating with a price target implying nearly 38% upside add to the bullish case—the largest implied upside on this list.
Unilever plc ADR: A Failed Breakout Into a Major Support Zone
Unilever plc (NYSE: UL) closes out the list as a consumer-defensive giant that pulled back sharply after failing to sustain a breakout above $70. That failure sent the stock quickly back into a key support zone near $60, resetting the forward P/E to 15.9 and pushing the RSI down to 27—deeply oversold. The stock also yields about 3.4%, offering an income cushion while investors wait for a recovery.
What makes Unilever interesting at this level is the higher-timeframe context: despite the near-term breakdown, the stock remains above key moving averages on the monthly chart and sits on a significant long-term support zone near $62.
Analyst sentiment is more neutral, with a consensus Hold rating, and institutional activity has been relatively flat, with inflows roughly offsetting outflows. Still, an RSI of 27 combined with a sharp flush into major support makes Unilever a compelling oversold watch candidate for investors and short-term traders alike.
If buyers step in and support holds, Unilever could set up for a strong oversold bounce.
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
Author: Leo Miller. Date Posted: 3/15/2026.
Key Points
- Eli Lilly is opening up a new way for employers to cover their weight-loss drugs.
- With half or more of employees not having coverage for obesity medications, Employer Connect could unlock significant demand for LLY.
- Meanwhile, the company's oral GLP-1 just beat out Novo's in a head-to-head type 2 diabetes duel.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
The world's most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), continued to assert its dominance in the weight-loss and diabetes drug market in 2026.
The company's most recent earnings report forecast robust 25% growth for the year, well above expectations. While that would be slower than the 45% growth Lilly generated in 2025, it would still mark the company's third-highest annual growth rate in its history. Lilly's current GLP-1 franchises should continue to post strong sales increases, but growth can't remain at sky-high levels forever.
Ground-zero (Ad)
San Francisco is the strangest city in America right now—you can hop into a self-driving car and be chauffeured by a robot, but out the window you see addicts slumped in doorways, open-air drug markets, the mentally ill screaming at the sky, and entire city blocks consumed by homeless encampments. It's ground-zero for the most disruptive technological forces of our age, and Erez lives in the Bay Area plugged into the capital, the connections, and the companies reshaping the world—the advancements in AI, blockchain, computing, and biosciences are unlike anything the world has seen before, and a tsunami of disruption is coming for everything all at once. During our most recent broadcast, we exposed what we're calling the most asymmetric opportunity of our careers: an overlooked financial company hiding a multi-billion-dollar blockchain asset Wall Street hasn't priced in—it's one of those rare situations Warren Buffett would describe as raining gold when all you have to do is step outside if you want to get rich.
Watch the broadcast before the window closes nowAt the same time, Lilly's top competitor, Novo Nordisk A/S (NYSE: NVO), is forecasting its weakest revenue growth rate in years. In 2026, Novo expects sales to fall by between 5% and 13%. When measured in U.S. dollars, the company hasn't experienced a revenue drop of more than 5% since 2014; measured in Danish kroner, that holds true through 1998.
The contrast highlights Lilly's stronger position, particularly for the injectable GLP-1s currently available.
Still, the healthcare company is making additional moves to solidify its lead. Expanding access to its drugs and winning the oral GLP-1 battle are two key levers Lilly is pulling.
Employer Connect: Lilly's Bid to Crack the Huge Employer Coverage Gap
One of Lilly's most significant recent announcements is the launch of its Employer Connect platform. The goal is to fill a major gap in employer-sponsored obesity care: Lilly notes that roughly half of people on employer-sponsored plans lack coverage for obesity medications. One survey found that just 20% of companies with more than 200 workers cover weight-loss drugs, and only 43% of companies with 5,000 or more employees do so.
That represents a substantial untapped opportunity for Lilly. If employers won't provide coverage, patients must pay out of pocket. Through LillyDirect, the firm's direct-to-consumer platform, Zepbound costs between $299 and $449 per month. At those prices, Lilly is likely losing many potential patients who would use its drugs if employers covered them.
To address this, Lilly is offering Zepbound to employers at a discounted rate—$449 per month—while employees would pay only a small share. That employer price is less than half of the drug's list price of more than $1,000. Employer Connect also bypasses traditional pharmacy benefit managers (PBMs), which act as middlemen between drug companies and insurers and often have opaque pricing agreements. The PBM industry is highly concentrated, giving those firms significant negotiating leverage.
Through Employer Connect, companies can select from more than 15 independent program administrators, allowing employers to pick the administrator whose services best meet their needs. Lilly's goal is to foster competition among these administrators based on the services they provide.
If employers adopt the program, Lilly could see meaningful new Zepbound sales flow into its top line, although a sizable contribution may not materialize until 2027 as employers evaluate the option. There is also a risk: if employers that already cover Zepbound migrate to Employer Connect, Lilly might take a pricing hit. Given the large coverage gap, however, Lilly appears willing to accept lower per-unit pricing in exchange for much higher volume.
Lilly Scores Win in Smaller Oral Type 2 Diabetes Market
Lilly also reported positive results for its investigational oral GLP-1, orforglipron. In a head-to-head trial against Novo's approved oral GLP-1, oral semaglutide (marketed as Rybelsus), orforglipron produced superior blood-sugar reduction and greater weight loss in patients with type 2 diabetes.
A1C, a key blood-sugar marker, fell by 2.2% for orforglipron patients versus 1.4% for oral semaglutide patients. Orforglipron patients also lost 9.2% of their body weight, compared with 5.3% for oral semaglutide patients.
Those data are encouraging as Lilly seeks approval for orforglipron as an oral treatment for type 2 diabetes. Still, the oral type 2 diabetes market is relatively small compared with the broader GLP-1 market. Novo's Rybelsus generated roughly $3.5 billion in sales in 2025—about one-tenth of the roughly $32.5 billion in combined Ozempic and Wegovy sales Novo reported that year. Lilly is also pursuing approval of orforglipron for obesity, which could address a much larger market.
LLY Keeps Opening New Doors to Drive Potential Growth
Overall, Lilly continues to expand potential customer bases by increasing drug access and advancing new products. Though it has already grown into a giant, the company's recent results and ongoing innovation make it difficult to bet against.
to bring you the latest market-moving news.
This email message is a sponsored message provided by Porter & Company, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights reserved.
345 North Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. United States of America..
0 Response to "Warning signs going into overdrive"
Post a Comment